3 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 5 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow CPG-oligonucleotide: new trials by email Literature Review of CPG-oligonucleotide trials Research Report on CPG-oligonucleotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN - Liver Metastasis Colon Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Saskatchewan | 12 | 2025-07-01 | 2024-08-09 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors CpG-ODN - Lung Cancer, Hepatocellular Carcinoma | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 50 | 2021-03-01 | 2024-06-26 |
| Safety and Immunogenicity Study of Na-GST-1 With or Without CpG Na-GST-1/Alhydrogel®, CpG 10104 - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 24 | 2014-10-01 | 2025-07-04 |
| A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) GNKG168 - Leukemia | Phase 1 | Terminated | SBI Biotech Co., Ltd. | 18 | 2009-09-01 | 2014-12-23 |
| Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine - Breast Cancer | Early Phase 1 | Completed | Mayo Clinic | 45 | 2008-08-28 | 2018-10-31 |
| Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma CpG-ODN - Glioblastoma | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 80 | 2005-09-01 | 2012-12-13 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Ancylostomiasis (1) · Anemia, Iron-Deficiency (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Glioblastoma (1) · Hookworm Infections (1) · Leukemia (1) · Lung Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Neglected Diseases (1)
Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · City of Hope Medical Center (1) · Mayo Clinic (1) · SBI Biotech Co., Ltd. (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · University of Saskatchewan (1)
United States (3) · China (1) · France (1)
Barbara A Pockai, M.D. (1) · David Diemert, MD (1) · Edith A Perez, M.D. (1) · Lihua E Budde (1) · Svetomir Markovic, MD, PhD (1) · Zhenfeng Zhang, MD, PhD (1)
P30CA015083 (1), P30CA033572 (1), P50CA107399 (1)